Janssen knows about market access and knows the pain points of the patient pathway; the start-ups have both the creative ideas and the technology. Together, we are able to solve issues. Q: Janssen is a member of new consortium of pharmaceutical, technology and academic partners who have come together under the "MELLODDY" (Machine Learning Ledger Orchestration for Drug Discovery) project which aims, for the first time, to use machine learning methods on the chemical libraries of 10 pharma companies and to develop a platform creating more accurate models to predict which compounds could be promising in the later stages of drug discovery and development. Why did Janssen join and what do you hope the project will achieve? QE: This is a great project. Janssen is in the lead along with nine pharmaceutical companies: Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Merck KgaA, Novartis, and Institut de Recherches Servier.